TITLE

Review: Omalizumab added to corticosteroids reduces exacerbations and corticosteroid use in adults and children with asthma

AUTHOR(S)
Thien, Francis
PUB. DATE
May 2011
SOURCE
ACP Journal Club;5/15/2011, Vol. 154 Issue 5, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study which noted whether subcutaneous omalizumab is safe and effective when added to corticosteroid therapy in treating adults and children with moderate-to-severe, persistent, allergic asthma. The study was conducted by researcher G.J. Rodrigo and colleagues, and was published in a 2011 issue of the journal "Chest." The study revealed that subcutaneous omalizumab added to corticosteroid therapy reduces exacerbations.
ACCESSION #
64279653

 

Related Articles

  • Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma. Thomson, Neil C. // Evidence Based Medicine;Aug2014, Vol. 19 Issue 4, p135 

    The author discusses the study on the effectiveness and safety of omalizumab in treating adults and children with moderate-to-severe persistent allergic asthma receiving inhaled corticosteroids (ICS) therapy. The study conducts a systematic review and meta-analysis of randomised controlled...

  • 2011 - Review: Omalizumab added to corticosteroids reduces exacerbations and corticosteroid use in adults and children with asthma. Thien, Francis // ACP Journal Club;5/15/2011, Vol. 154 Issue 5, p10 

    Question In adults and children with moderate-to-severe, persistent, allergic asthma, is subcutaneous omalizumab safe and efficacious when added to corticosteroid therapy? Review scope Included studies compared subcutaneous omalizumab with placebo as add-on therapy to corticosteroids in children...

  • Omalizumab: the evidence for its place in the treatment of allergic asthma. McNicholl, Diarmuid M.; Heaney, Liam G. // Core Evidence;2008, Vol. 3 Issue 1, p55 

    Introduction: Asthma is a chronic inflammatory airways disease associated with reversible airflow obstruction and bronchial hyperresponsiveness. Asthma is prevalent worldwide and results in significant morbidity, mortality, and healthcare costs, the majority of which arise from those with severe...

  • Omalizumab: An update on efficacy and safety in moderate-to-severe allergic asthma. Chipps, Bradley E.; Figliomeni, Maria; Spector, Sheldon // Allergy & Asthma Proceedings;Sep/Oct2012, Vol. 33 Issue 5, p377 

    Omalizumab is an anti-immunoglobulin E (anti-IgE) monoclonal antibody approved in the United States since 2003 for treatment of moderate-to-severe allergic asthma in adults and adolescents (aged =12 years) inadequately controlled with inhaled corticosteroids (ICSs). Current treatment guidelines...

  • Omalizumab as a new therapeutic approach for children with severe asthma. Jerzyńska, Joanna; Sztafińska, Anna; Woicka-Kolejwa, Katarzyna; Stelmach, Iwona // Advances in Dermatology & Allergology / Postepy Dermatologii i A;Feb2014, Vol. 31 Issue 1, p45 

    Omalizumab has been shown to improve asthma control when added to a regimen of guideline-based therapy for inner-city children and adolescents, nearly eliminating seasonal peaks in exacerbation and reducing the need for other medications to control asthma. Below, we describe a case of a...

  • Omalizumab: Clinical Use for the Management of Asthma. Thomson, Neil C.; Chaudhuri, Rekha // Clinical Medicine Insights: Circulatory, Respiratory & Pulmonary;2012, Issue 6, p27 

    Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a treatment option for patients with moderate to severe allergic asthma whose asthma is poorly controlled with inhaled corticosteroids and inhaled long-acting β2 agonist bronchodilators. This review considers...

  • Treating Exacerbations of Asthma in Children: The Role of Systemic Corticosteroids. South, Mike; Rachelefsky, Gary // Internet Journal of Pediatrics & Neonatology;2005, Vol. 5 Issue 1, p35 

    This article focuses on a study whose objective was to review the use of systemic corticosteroids to treat recurrent, acute asthma episodes in children, with a focus on the role of oral corticosteroids. A comprehensive review of the literature was performed. Early treatment of acute asthma...

  • Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Lai, Tianwen; Wang, Shaobin; Xu, Zhiwei; Zhang, Chao; Zhao, Yun; Hu, Yue; Cao, Chao; Ying, Songmin; Chen, Zhihua; Li, Wen; Wu, Bin; Shen, Huahao // Scientific Reports;2/6/2015, p8191 

    Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled...

  • Omalizumab: A Review of its Use in the Treatment of Allergic Asthma. Plosker, Greg L.; Keam, Susan J. // BioDrugs;2008, Vol. 22 Issue 3, p189 

    Omalizumab, a monoclonal antibody that targets circulating IgE, is approved as add-on therapy for adult and adolescent patients with severe allergic asthma in the EU and moderate to severe allergic asthma in the US. Several randomized, double-blind trials have demonstrated the therapeutic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics